Meeting
2022 ASCO Annual Meeting
STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults.
Authors
Catherine Michelle Albert
Seattle Children's Research Institute, Seattle, WA
Catherine Michelle Albert , Navin R. Pinto , Mallory Taylor , Ashley Wilson , Stephanie Rawlings-Rhea , Stephanie Mgebroff , Christopher Brown , Catherine Lindgren , Wenjun Huang , Kristy Seidel , Prabha Narayanaswany , Vicky Wu , Erin R. Rudzinski , Nicholas A. Vitanza , Juliane Gust , Rebecca Alice Gardner , Michael C. Jensen , Julie R. Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03618381
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2541)
DOI
10.1200/JCO.2022.40.16_suppl.2541
Abstract #
2541
Poster Bd #
196
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.
First Author: Jiuwei Cui
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells.
First Author: Jennifer M Specht
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke